The Silent Revolution in Brain Tumor Care: How Genomics and Wearables Are Changing the Game
Did you know that the way we treat brain tumors has undergone a seismic shift in the last decade? It’s not just about what the tumor looks like under a microscope anymore—it’s about understanding its genetic blueprint. But here’s where it gets controversial: while this genomic revolution promises more precise treatments, it also raises questions about accessibility and the ethical implications of personalized medicine. Let’s dive in.
In a recent episode of Cleveland Clinic’s Neuro Pathways podcast, Andrew Dhawan, MD, PhD, a physician-scientist at the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, reveals how genomic advancements are transforming brain tumor management. Dr. Dhawan explains, ‘The biggest leap in the past five to ten years has been the genomic revolution. We’re no longer just looking at tumors under a microscope; we’re decoding their biology through tools like whole exome sequencing and methylation arrays. This allows us to pinpoint tumor subtypes and tailor treatments with unprecedented accuracy.’
Hosted by Glen Stevens, DO, PhD, the podcast explores cutting-edge developments in brain tumor diagnostics and therapy, with a spotlight on glioblastoma—a notoriously aggressive tumor type. Here’s what they cover:
- Glioblastoma Unpacked: Why this tumor is so challenging to treat and what’s being done about it.
- Genomics and Methylation: How these molecular diagnostics are reshaping our approach to brain cancer.
- Spinal Fluid Analysis: A new frontier in detecting tumor biomarkers.
- Tumor Resistance: Why some tumors outsmart treatments and how we’re fighting back.
- Wearable Tech in Neuro-Oncology: How smartwatches and smartphones are becoming game-changers in patient monitoring.
And this is the part most people miss: Wearable devices aren’t just for tracking steps anymore. Dr. Dhawan’s team is using them to monitor patients with glioblastoma in real time, tracking actigraphy measures like walking speed, heart rate, and even gait steadiness. ‘We’re finding that changes in these metrics can predict complications—like thromboembolic events—and tumor progression before they show up on an MRI,’ he explains. For instance, a sudden shift in heart rate variability could signal a pulmonary embolism (PE), a life-threatening complication affecting 30% of glioblastoma patients.
Dr. Stevens brings up a thought-provoking study: Patients with high-grade astrocytomas who exercised regularly lived twice as long as those who didn’t. ‘Are we doing enough to encourage physical activity in our patients?’ he asks. Dr. Dhawan admits they’re not yet nudging patients to exercise but are closely monitoring step counts, which have emerged as a strong indicator of tumor progression. ‘When the tumor worsens, walking and movement are often the first things to decline,’ he notes.
Controversial Question: As we rely more on wearables and genomics, are we risking over-medicalization of patient care? Or are these tools the future of personalized medicine? Let us know your thoughts in the comments.
Listen to the full 27-minute episode via the podcast player above or read the edited transcript below. For more episodes, visit Cleveland Clinic’s Neuro Pathways or your favorite podcast platform. This activity is eligible for AMA PRA Category 1 Credit™ and ANCC contact hours—claim yours here after listening.
